neffy® (epinephrine nasal spray)
Emergency treatment of severe allergic reactions (Type I), including anaphylaxis
ApprovedCommercial Stage
Key Facts
Indication
Emergency treatment of severe allergic reactions (Type I), including anaphylaxis
Phase
Approved
Status
Commercial Stage
Company
About ARS Pharmaceuticals
ARS Pharmaceuticals is on a mission to transform the treatment of severe allergic reactions by developing needle-free, patient-friendly therapies. Its transformative achievement is the 2024 FDA approval of neffy®, the first needle-free epinephrine nasal spray, which directly tackles the underutilization of epinephrine due to fear, complexity, and portability issues with auto-injectors. The company's strategy is to commercialize neffy® in the substantial anaphylaxis market while advancing its intranasal platform into adjacent Type I hypersensitivity indications like urticaria, aiming to capture significant market share from entrenched auto-injector competitors.
View full company profile